/FEMY
FEMY Stock - Femasys Inc.
Healthcare|Medical - Instruments & SuppliesNASDAQ
$0.86+7.97%
+$0.06 (+7.97%) • Dec 19
70
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.62
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $0.95
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for FEMY
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.85 – $0.87
TARGET (TP)$0.99
STOP LOSS$0.79
RISK/REWARD1:1.8
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta-2.58
52W High$1.80
52W Low$0.31
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $1.63M | $1.07M | $1.21M | $1.18M | $1.04M |
| Gross Profit | $1.08M | $691,901 | $764,280 | $809,305 | $731,385 |
| Gross Margin | 66.6% | 64.5% | 63.4% | 68.6% | 70.5% |
| Operating Income | $-17,785,805 | $-14,508,415 | $-11,600,264 | $-8,336,804 | $-6,933,143 |
| Net Income | $-18,816,628 | $-14,247,124 | $-11,394,170 | $-7,537,845 | $-6,914,992 |
| Net Margin | -1155.0% | -1329.1% | -944.6% | -639.0% | -666.2% |
| EPS | $-0.84 | $-0.93 | $-0.97 | $-0.64 | $-0.59 |
Company Overview
Femasys Inc., a biomedical company, focuses on women's healthcare market in the United States. The company develops permanent birth control solutions, such as FemBloc and FemChec; FemaSeed, an artificial insemination solution; FemCerv, a biopsy device for endocervical curettage; and FemEMB, a product candidate for endometrial sampling in support of uterine cancer detection testing. It also commercializes FemVue saline-air device in the United States, Europe, Canada, Japan, and internationally. The company offers its infertility products to obstetrics-gynecological physicians, related healthcare professionals, women's healthcare provider organizations, and reproductive endocrinologists. In addition, it provides non-surgical product technologies. Femasys Inc. was incorporated in 2004 and is based in Suwanee, Georgia.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
1
100%
Hold / Neutral
0%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
1 Bullish0 Neutral/Bearish
Price Targets
$7
Average Target
↑ 654.8% Upside
Now
$7
Low
$7
Average
$7
High
Based on 1 analyst
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| November 20th 2025 | Laidlaw | Initiation | Buy | $6.5 |
Earnings History & Surprises
FEMYBeat Rate
47%
Last 17 quarters
Avg Surprise
+0.5%
EPS vs Estimate
Beats / Misses
8/8
1 met exactly
Latest EPS
$-0.10
Q4 2025
EPS Surprise History
Q1 24
0.0%
$-0.19vs$-0.19
Q2 24
+22.7%
$-0.17vs$-0.22
Q3 24
-16.7%
$-0.21vs$-0.18
Q4 24
-20.0%
$-0.24vs$-0.20
Q1 25
+8.0%
$-0.23vs$-0.25
Q2 25
-35.3%
$-0.23vs$-0.17
Q3 25
+11.1%
$-0.16vs$-0.18
Q4 25
+13.0%
$-0.10vs$-0.12
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 26, 2026 | — | — | — | — |
Q4 2025 | Nov 14, 2025 | $-0.12 | $-0.10 | +13.0% | ✓ BEAT |
Q3 2025 | Aug 8, 2025 | $-0.18 | $-0.16 | +11.1% | ✓ BEAT |
Q2 2025 | May 8, 2025 | $-0.17 | $-0.23 | -35.3% | ✗ MISS |
Q1 2025 | Mar 27, 2025 | $-0.25 | $-0.23 | +8.0% | ✓ BEAT |
Q4 2024 | Nov 12, 2024 | $-0.20 | $-0.24 | -20.0% | ✗ MISS |
Q3 2024 | Aug 8, 2024 | $-0.18 | $-0.21 | -16.7% | ✗ MISS |
Q2 2024 | May 9, 2024 | $-0.22 | $-0.17 | +22.7% | ✓ BEAT |
Q1 2024 | Mar 28, 2024 | $-0.19 | $-0.19 | 0.0% | = MET |
Q4 2023 | Nov 14, 2023 | $-0.25 | $-0.26 | -4.0% | ✗ MISS |
Q3 2023 | Aug 10, 2023 | $-0.19 | $-0.22 | -15.8% | ✗ MISS |
Q2 2023 | May 11, 2023 | $-0.26 | $-0.25 | +3.8% | ✓ BEAT |
Q1 2023 | Mar 30, 2023 | $-0.26 | $-0.24 | +7.7% | ✓ BEAT |
Q4 2022 | Nov 10, 2022 | $-0.23 | $-0.25 | -8.7% | ✗ MISS |
Q3 2022 | Aug 10, 2022 | $-0.26 | $-0.22 | +15.4% | ✓ BEAT |
Q2 2022 | May 11, 2022 | $-0.21 | $-0.24 | -14.3% | ✗ MISS |
Q1 2022 | Mar 24, 2022 | $-0.25 | $-0.08 | +68.0% | ✓ BEAT |
Q4 2021 | Nov 10, 2021 | $-0.15 | $-0.19 | -26.7% | ✗ MISS |
Q3 2021 | Aug 11, 2021 | — | $-0.52 | — | — |
Q2 2021 | Jun 21, 2021 | — | $-0.18 | — | — |
Latest News
Femasys shares are trading higher after the company announced that it has received 510(k) clearance from the FDA for its FemVue Controlled device.
📈 PositiveBenzinga•Dec 18, 2025, 05:36 PM
Femasys Receives 510(k) Clearance From FDA For FemVue Controlled Device, Diagnostic Solution For Controlled Contrast Delivery To Evaluate Fallopian Tube Status
📈 PositiveBenzinga•Dec 18, 2025, 02:16 PM
PharmaCyte Biotech shares are trading higher after the company announced monetization of its stake in Femasys.
📈 PositiveBenzinga•Nov 25, 2025, 03:42 PM•Also:
PharmaCyte Biotech Monetizes Femasys Stake; Cash And Securities Expected At ~$20M After Monetization, Up From $13.3M
📈 PositiveBenzinga•Nov 25, 2025, 02:19 PM•Also:
Femasys shares are trading higher after Laidlaw initiated coverage on the stock with a Buy rating and announced a $6.50 price target.
📈 PositiveBenzinga•Nov 20, 2025, 05:30 PM
Laidlaw & Co. Initiates Coverage On Femasys with Buy Rating, Announces Price Target of $6.5
📈 PositiveBenzinga•Nov 20, 2025, 02:44 PM
Femasys Q3 EPS $(0.10) Beats $(0.12) Estimate, Sales $729.394K Miss $1.450M Estimate
➖ NeutralBenzinga•Nov 14, 2025, 09:05 PM
Femasys Announces ~$500K Initial Order For Launch Of Permanent Birth Control In France And Benelu Region Through Partnership With Kebomed
📈 PositiveBenzinga•Nov 10, 2025, 02:06 PM
Femasys gets FDA OK for final FemBloc trial, secures $12M financing, stock surges
📈 PositiveSeeking Alpha•Nov 3, 2025, 02:30 PM
Femasys shares are trading higher after the company announced FDA clearance to continue enrollment in the final phase of its FINALE trial for FemBloc and entered agreements to issue $12M in notes and warrants, potentially raising up to $58M.
📈 PositiveBenzinga•Nov 3, 2025, 01:35 PM
Femasys Announces FDA Investigational Device Exemption To Continue Enrollment In Final Phase Of FINALE Trial For FemBloc; Also Enters Agreements To Issue $12M Principal Amount Notes And Warrants For Potential Total Of $58M
📈 PositiveBenzinga•Nov 3, 2025, 01:33 PM
Femasys Announces Start Of Post-Market Surveillance Clinical Study For Its CE-Marked FemBloc Permanent Birth Control, Conducted Under EU Medical Device Regulation In Collaboration With Regional Medical Experts
📈 PositiveBenzinga•Oct 22, 2025, 01:03 PM
Shares of fertility stocks are trading lower amid possible profit taking after a report yesterday suggested that the White House is set to announce a proposal that would make IVF more accessible.
➖ NeutralBenzinga•Oct 17, 2025, 02:19 PM•Also: , ,
Deputy Director Of The White House Domestic Policy Council Says New Fertility Benefit Option For Employers To Offer To Employees
📈 PositiveBenzinga•Oct 16, 2025, 08:13 PM•Also: , ,
President Trump Says EMD Serono Will Largely Bring Back Production To The United States; Cost Of Per Cycle Will Fall By 73%; We Will Take Steps To Vastly Expand Coverage Of Fertility; Americans Will Be Able To Opt In To Specialized Coverage For Fertility
📈 PositiveBenzinga•Oct 16, 2025, 07:56 PM•Also: , ,
President Trump Says We Will Dramatically Slash Cost Of IVF; I Am Pleased To Announced EMD Serono Has Agreed To Provide Massive Discounts On Fertility Drugs Sold In The U.S.; EMD Serono Agrees That All Future Drugs Will Be Offset At Most Favored Nation Prices
➖ NeutralBenzinga•Oct 16, 2025, 07:52 PM•Also: , ,
Shares of fertility stocks are trading higher following a report suggesting that the White House is set to announce a proposal that would make IVF more accessible.
📈 PositiveBenzinga•Oct 16, 2025, 05:02 PM•Also: , ,
'White House Set To Announce Proposal Seeking To Make I.V.F. More Accessible' - NY Times
➖ NeutralBenzinga•Oct 16, 2025, 04:53 PM•Also: , ,
Femasys Partners With Kebomed To Commercialize FemBloc Permanent Birth Control In France And Benelux Region
📈 PositiveBenzinga•Sep 25, 2025, 01:05 PM
Femasys Partners With Medical Electronic Systems To Provide Advanced Sperm Analysis Technology
📈 PositiveBenzinga•Sep 22, 2025, 01:02 PM
Frequently Asked Questions about FEMY
What is FEMY's current stock price?
Femasys Inc. (FEMY) is currently trading at $0.86 per share. The stock has moved +7.97% today.
What is the analyst price target for FEMY?
No analyst price targets are currently available for this stock.
What sector is Femasys Inc. in?
Femasys Inc. operates in the Healthcare sector, specifically within the Medical - Instruments & Supplies industry. The company is traded on the NASDAQ exchange.
What is FEMY's market cap?
Femasys Inc. has a market capitalization of $0.03 billion, making it a small-cap company.
Does FEMY pay dividends?
No, Femasys Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorAIMD
Ainos, Inc.
$2.11
Mkt Cap: $0.0B
APLM
Apollomics, Inc.
$16.73
Mkt Cap: $0.0B
BCTX
BriaCell Therapeutics Corp.
$8.95
Mkt Cap: $0.0B
COCH
Envoy Medical, Inc.
$0.73
Mkt Cap: $0.0B
CRIS
Curis, Inc.
$1.07
Mkt Cap: $0.0B
DARE
Daré Bioscience, Inc.
$2.09
Mkt Cap: $0.0B
EKSO
Ekso Bionics Holdings, Inc.
$4.86
Mkt Cap: $0.0B
HBIO
Harvard Bioscience, Inc.
$0.75
Mkt Cap: $0.0B
PCSA
Processa Pharmaceuticals, Inc.
$3.78
Mkt Cap: $0.0B
VVOS
Vivos Therapeutics, Inc.
$1.97
Mkt Cap: $0.0B
Explore stocks similar to FEMY for comparison